TARGET RESEARCH ARTICLES
-
Drug Discovery AI Has A Ground Truth Problem
If the goal is more healthy years of life, the bottlenecks are target identification, target validation, and clinical testing. Why is AI not transforming those steps? Because the data are not there.
-
Wondering If Your Org Should Purchase R&D Datasets?
Pharma/biotech companies are increasingly looking to access large-scale data sets to fill gaps in their computational biology capabilities. Be prepared for the investment.
-
The Future Is Ancient: Evolution, Metabolics, And AI
We caught up with Hannah Gordon, Ph.D., chief scientific officer of Enveda, to discuss why the future may depend more on decoding nature’s evolutionarily selected chemistry.
-
Beyond Engineered Antibodies: Harnessing The Natural Human Repertoire
We caught up Srikanth Pendyala, MD, CMO of Infinimmune, to discuss the importance of learning directly from the human immune system itself in antibody research.
-
How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 of 3)
Rh incompatibility can make pregnancy dangerous. Rhogam helped protect my family and stands as a powerful example of unconventional drug discovery.
-
2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics
Startup founders of Resilientia Tx discuss protecting cancer patients from radiation side effects, organ-on-a-chip discovery, Nucleate Boston, and early startup challenges.
TARGET RESEARCH ARTICLES. APP NOTES, CASE STUDIES. & WHITE PAPERS
-
Well-designed lipid nanoparticles enable safe, efficient delivery. OVA-based models show how formulation choices shape efficacy, safety, and anti-tumor outcomes in melanoma research.
-
Gain mechanistic insights beyond traditional viability assays, revealing nuanced cellular phenotypes and strengthening early drug discovery decisions without sacrificing throughput or efficiency.
-
Structure‑enabled drug discovery revealed a novel, druggable binding site in Artemis, enabling rapid SAR optimization and a ~500‑fold potency improvement against a challenging oncology target.
-
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
New advances in chemomics, proteome mapping, and modern synthetic methods are redefining how quickly and precisely discovery teams can move from raw data to meaningful clinical momentum.
-
Sensitive digital PCR methods enable confident detection of low‑abundance iPSC markers. Gain insight into how these capabilities support more reliable monitoring and quality assessment.
TARGET RESEARCH SOLUTIONS
-
Macrocycles expand drug discovery into previously inaccessible targets. With validated success and flexible approaches, they provide a powerful path for tackling the most challenging biology.
-
CHO cells have been the workhorse for protein and antibody manufacturing. The major advantages of CHO include robust growth, hardiness in suspension culture, stellar protein production and secretion, and a long track record.
-
HEK293 cells have been the most popular mammalian transient production platform. The primary advantage of HEK293 cells is transfection efficiency.
-
The demand for high-throughput antibodies has exponentially increased over the last couple of years and has rapidly accelerated the antibody screening process.
-
E. coli is often the system of choice for biomanufacturing because of its amenability to genetic manipulation, low production cost, and rapid timelines for bioexpression.
-
Curia provides a wide range of biochemical and cell-based bioassay workflows to support Discovery, Research & Development as well as cGxP therapeutic testing campaigns
-
We deliver custom assay development, screening, potency, and selectivity testing services for the pharmaceutical, biopharmaceutical, and agrochemical industries.
-
Evaluating small and large molecule therapeutics within cellular environments is essential to understanding their efficacy, potency, and safety within a complex biological system.
-
Curia’s expert scientists use advanced technology to produce and analyze high-quality recombinant proteins.
-
Curia’s discovery biology team accelerates your program toward the clinic and commercialization with our best-in-class, customizable solutions.
-
At Curia, our team of expert protein chemists and structural biologists brings the advanced experience and technology needed to support all your structural biology services needs.
-
High‑throughput scNMT‑seq offers a powerful way to map methylation and transcriptional activity. Learn about strategies that cut variability and support dependable multi‑omics datasets.
-
Generate human-relevant data with an Organ-Chip system that combines automation, imaging, and cost efficiency for faster, more confident insights for drug development and complex biological studies.
-
With 12 independent Emulations in one consumable, Chip-Array optimizes workflows and reduces cell requirements—delivering scalable, physiologically relevant models for advanced research.